ABOUT US

Omniox is an IND stage biotechnology company founded based on H-NOX technology developed in Michael Marletta’s laboratory at the University of California, Berkeley. We are developing the breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs where tissue hypoxia drives disease pathology and worsens patient outcomes. Our in-house team is composed of experienced scientific and biotechnology professionals, and our advisory boards include world-leading experts in the appropriate fields of medicine, science, and business. Omniox has received grants and other funding from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors.

Vision

To pioneer innovative oxygen-based therapies that restore health to patients.

Mission

To solve difficult clinical problems where hypoxia plays a central role. Through rigorous science and world-class partnerships, we are developing our proprietary oxygen-delivery platform to provide meaningful therapeutic benefit to patients.

Values

Scientific and operational excellence
  • Passionate, versatile, and exceptional scientific teams
  • Transparent, effective and diligent business practices
Respect
  • Respected for the integrity and quality of our science
  • Respectful of employees, patients, investors and collaborators
Open-mindedness and courage
  • Curious about hard problems and creative in developing solutions
  • Fearless in the face of challenges and committed to successful outcomes

MANAGEMENT

John Wesley, CFA

VP Finance & Business Development

John Wesley joined Omniox in 2016 to lead business development and finance and has served on the board of directors since 2012. Prior to Omniox, John invested in public and private opportunities at Pequot Capital, H.I.G. Capital, and Concourse Capital. Prior to his investing career, John worked in strategic and financial advisory roles at Bain & Co. and Morgan Stanley. John received an MBA from the Wharton School and a B.S. in economics from Yale University. John is a CFA charterholder.

Ana Krtolica

Ana Krtolica, PhD

VP Research & Development

Ana Krtolica joined Omniox in 2012, became VP of Research in August 2013, and is currently VP of Research & Development, leading Biology and Translational teams focused on bringing novel OMX oxygen delivery drug candidates to the clinic in oncology and ischemic diseases. Prior to joining Omniox, Ana co-founded StemLifeLine, Inc., an early-stage drug discovery company, serving as their CEO and CSO for 6 years. Prior to industry, Ana worked as a career scientist at Lawrence Berkeley National Laboratory with a joint appointment at the University of California, San Francisco. Ana obtained her PhD in Biochemistry at the University of Rochester Cancer Center. Ana has been Principal Investigator on a number of research grants, authored multiple patent applications, and published more than 30 research papers in peer-reviewed journals, as well as a number of reviews and book chapters.

Jonathan Winger, PhD

Co-Founder and VP Process Development & New Product Introduction

Jonathan Winger is co-inventor of the H-NOX technology from which OMX therapeutics are derived, and has 20+ years of experience with production and study of H-NOX and other proteins. At Omniox, he oversees the design, production, and characterization of protein variants with different kinetic and stability profiles, and manages process and analytical development for candidate OMX therapeutics. Prior to Omniox, Jonathan was an American Heart Association Postdoctoral Fellow at the University of California, Berkeley, where he used structural biology techniques including X-ray crystallography, small-angle X-ray scattering, and NMR to study H-NOX proteins, kinases, and other proteins. He obtained his PhD in Medicinal Chemistry at the University of Michigan, where he used spectroscopy and enzymology to study the role of soluble guanylate cyclase (sGC), an H-NOX-containing protein, in nitric oxide signaling pathways. Insights gained from this work contributed to the conception and founding of Omniox. Jonathan has published numerous research papers and abstracts, co-authored several book chapters, and is an inventor on multiple patents.

Davis Bauman

Davis Bauman

Senior Director, Quality Assurance

Davis Bauman joined Omniox in 2018 and is responsible for leading Quality Assurance. He has more than 20 years of quality-related experience in positions with XOMA, Onyx Pharmaceuticals, Carbylan Therapeutics and Anthera Pharmaceuticals. Davis holds a bachelor’s degree in chemistry from Oberlin College.